0QSS.L

ERYTECH Pharma S.A. [0QSS.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

0QSS.L Stock Summary

Top 10 Correlated Stocks

0QSS.L

In the News

0QSS.L Financial details

Company Rating
-
Market Cap
17.43M
Income
-35.28M
Revenue
944K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
49
Optionable
No
Shortable
Yes
Earnings
25 Sep 2024
P/E
-2.24
Forward P/E
-
PEG
-0
P/S
4.71
P/B
0.73
P/C
-
P/FCF
-2.26
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-41.81
EPS next Y
-
EPS next Q
-
EPS this Y
6702.72%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-32.21%
Revenue last 5Y
-21.17%
Revenue Q/Q
138.07%
EPS Q/Q
97.87%
-
-
-
-
SMA20
-32%
SMA50
-70.52%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-
ROE
-36%
ROC
-
Gross Margin
100%
Oper. Margin
-272%
Profit Margin
-210%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0-11.02
52W High
-
52W Low
-
RSI
36.04
Rel Volume
415.24
Avg Volume
21
Volume
8.72K
Perf Week
-38.92%
Perf Month
-77.71%
Perf Quarter
-
Perf Half Y
-75.35%
-
-
-
-
Beta
1.794
-
-
Volatility
0.15%, 0.29%
Prev Close
-0.71%
Price
0.419
Change
3.97%

Something similar

Top by Market Cap
FB2A.DE
MSF.DE
AMZ.DE
DHR-PB
AVGO
Same Sector
300677.SZ
1061.HK
6978.HK
REG1V.HE
CDNA
Top Correlated Stocks
0413.HK
VESTL.IS
ISCTR.IS
Similar Market Cap
FBPI
DLPN
SBTX.L
7348.HK
ALNXT.PA

Company Profile

Healthcare Medical - Pharmaceuticals
  • Volume Average 21
  • Market Capitalization 17.43M
  • Employee 49
  • CEO Mr. Eric Soyer Ph.D.
  • Headquarters Lyon,FR
  • IPO Date 2014-09-19
  • Website https://www.erytech.com

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.